Analysts: Lipitor may live longer than we think

Could it be that Pfizer's Lipitor won't suffer an immediate K.O. punch from generic competition? Rather than the sudden-and-sharp loss of billions in Lipitor revenues, Pfizer might actually see a slow-but-steady erosion, a new analyst report suggests.

As Forbes reports, Sanford C. Bernstein analysts are theorizing that a variety of factors--Ranbaxy Laboratories' manufacturing problems, Pfizer's aggressive fight to delay as many Lipitor generics as possible--could together give Pfizer a softer landing. This theory revolves around the fact that prices for a newly generic drug don't really plummet until several companies are marketing copycats. Patients are more likely to stick with the brand name until that happens.

Pfizer has made a deal with Watson Pharmaceuticals for an authorized generic to debut in November 2011. Teva Pharmaceutical Industries is also in the mix, having already launched a version in Canada. Ranbaxy also has the right to launch then, but if it can't get its act together in time, that means one fewer generic rival--and more potential revenue for Pfizer. 

- read the Forbes story

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.